VarCov Co’s Taysha Gene Therapies TSHA Stock Holding History

VarCov Co’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-58,511	Closed	-$262K	–	560
2026 Q1	$262K	Buy	+58,511	New	+$272K	0.1%	311

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VarCov Co's TSHA Position: Q2 2026 in Review

VarCov Co sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 58,511 shares — an estimated $262K sold.

VarCov Co first reported a position in TSHA in Q1 2026 and held it in 1 quarter. The position peaked at $262K in Q1 2026. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

VarCov Co reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
VarCov Co sold 58,511 Taysha Gene Therapies shares in Q2 2026, an estimated $262K.
VarCov Co first reported a position in Taysha Gene Therapies in Q1 2026 and held it in 1 quarter.
VarCov Co's Taysha Gene Therapies position peaked at $262K in Q1 2026.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.